Chronic Plaque Psoriasis-Pipeline Review, H1 2015

Chronic Plaque Psoriasis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6048IDB
  • |
  • Pages: 109
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chronic Plaque Psoriasis-Pipeline Review, H1 2015


Global Markets Direct's, 'Chronic Plaque Psoriasis-Pipeline Review, H1 2015', provides an overview of the Chronic Plaque Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chronic Plaque Psoriasis Overview 8

Therapeutics Development 9

Pipeline Products for Chronic Plaque Psoriasis-Overview 9

Pipeline Products for Chronic Plaque Psoriasis-Comparative Analysis 10

Chronic Plaque Psoriasis-Therapeutics under Development by Companies 11

Chronic Plaque Psoriasis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Chronic Plaque Psoriasis-Products under Development by Companies 15

Chronic Plaque Psoriasis-Companies Involved in Therapeutics Development 16

AbGenomics International, Inc. 16

Actelion Ltd 17

Almirall, S.A. 18

ApoPharma Inc. 19

Biotest AG 20

Boehringer Ingelheim GmbH 21

Can-Fite BioPharma Ltd. 22

Coherus BioSciences, Inc. 23

Covagen AG 24

Eli Lilly and Company 25

GlaxoSmithKline plc 26

Mitsubishi Tanabe Pharma Corporation 27

Novartis AG 28

OPKO Health, Inc. 29

Pfizer Inc. 30

Sandoz Inc. 31

Sun Pharmaceutical Industries Inc. 32

Takeda Pharmaceutical Company Limited 33

UCB S.A. 34

XenoPort, Inc. 35

Chronic Plaque Psoriasis-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

AbGn-168H-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

adalimumab biosimilar-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

baricitinib-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

BI-655066-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

certolizumab pegol-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

CF-101-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

CJM-112-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

COVA-322-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

dimethyl fumarate-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

etanercept biosimilar-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

etanercept biosimilar-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

GSK-2831781-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ixekizumab-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

lunacalcipol-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

MT-1303-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

namilumab-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

orilotimod-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

PF-06263276-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

ponesimod-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

tildrakizumab-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

tregalizumab-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

XP-23829-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Chronic Plaque Psoriasis-Recent Pipeline Updates 80

Chronic Plaque Psoriasis-Dormant Projects 102

Chronic Plaque Psoriasis-Discontinued Products 103

Chronic Plaque Psoriasis-Product Development Milestones 104

Featured News & Press Releases 104

Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis 104

Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 104

Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 106

Appendix 108

Methodology 108

Coverage 108

Secondary Research 108

Primary Research 108

Expert Panel Validation 108

Contact Us 109

Disclaimer 109

List of Tables

Number of Products under Development for Chronic Plaque Psoriasis, H1 2015 9

Number of Products under Development for Chronic Plaque Psoriasis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Chronic Plaque Psoriasis-Pipeline by AbGenomics International, Inc., H1 2015 16

Chronic Plaque Psoriasis-Pipeline by Actelion Ltd, H1 2015 17

Chronic Plaque Psoriasis-Pipeline by Almirall, S.A., H1 2015 18

Chronic Plaque Psoriasis-Pipeline by ApoPharma Inc., H1 2015 19

Chronic Plaque Psoriasis-Pipeline by Biotest AG, H1 2015 20

Chronic Plaque Psoriasis-Pipeline by Boehringer Ingelheim GmbH, H1 2015 21

Chronic Plaque Psoriasis-Pipeline by Can-Fite BioPharma Ltd., H1 2015 22

Chronic Plaque Psoriasis-Pipeline by Coherus BioSciences, Inc., H1 2015 23

Chronic Plaque Psoriasis-Pipeline by Covagen AG, H1 2015 24

Chronic Plaque Psoriasis-Pipeline by Eli Lilly and Company, H1 2015 25

Chronic Plaque Psoriasis-Pipeline by GlaxoSmithKline plc, H1 2015 26

Chronic Plaque Psoriasis-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 27

Chronic Plaque Psoriasis-Pipeline by Novartis AG, H1 2015 28

Chronic Plaque Psoriasis-Pipeline by OPKO Health, Inc., H1 2015 29

Chronic Plaque Psoriasis-Pipeline by Pfizer Inc., H1 2015 30

Chronic Plaque Psoriasis-Pipeline by Sandoz Inc., H1 2015 31

Chronic Plaque Psoriasis-Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 32

Chronic Plaque Psoriasis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 33

Chronic Plaque Psoriasis-Pipeline by UCB S.A., H1 2015 34

Chronic Plaque Psoriasis-Pipeline by XenoPort, Inc., H1 2015 35

Assessment by Monotherapy Products, H1 2015 36

Number of Products by Stage and Target, H1 2015 38

Number of Products by Stage and Mechanism of Action, H1 2015 40

Number of Products by Stage and Route of Administration, H1 2015 42

Number of Products by Stage and Molecule Type, H1 2015 44

Chronic Plaque Psoriasis Therapeutics-Recent Pipeline Updates, H1 2015 80

Chronic Plaque Psoriasis-Dormant Projects, H1 2015 102

Chronic Plaque Psoriasis-Discontinued Products, H1 2015 103

List of Figures

Number of Products under Development for Chronic Plaque Psoriasis, H1 2015 9

Number of Products under Development for Chronic Plaque Psoriasis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 36

Number of Products by Top 10 Targets, H1 2015 37

Number of Products by Stage and Top 10 Targets, H1 2015 38

Number of Products by Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Top 10 Routes of Administration, H1 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 43

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbGenomics International, Inc.

Actelion Ltd

Almirall, S.A.

ApoPharma Inc.

Biotest AG

Boehringer Ingelheim GmbH

Can-Fite BioPharma Ltd.

Coherus BioSciences, Inc.

Covagen AG

Eli Lilly and Company

GlaxoSmithKline plc

Mitsubishi Tanabe Pharma Corporation

Novartis AG

OPKO Health, Inc.

Pfizer Inc.

Sandoz Inc.

Sun Pharmaceutical Industries Inc.

Takeda Pharmaceutical Company Limited


XenoPort, Inc.

Chronic Plaque Psoriasis Therapeutic Products under Development, Key Players in Chronic Plaque Psoriasis Therapeutics, Chronic Plaque Psoriasis Pipeline Overview, Chronic Plaque Psoriasis Pipeline, Chronic Plaque Psoriasis Pipeline Assessment

select a license

Single User License
USD 2000 INR 143760
Site License
USD 4000 INR 287520
Corporate User License
USD 6000 INR 431280



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]